Alzheimer's disease
Top Cited Papers
- 15 October 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Reviews Disease Primers
- Vol. 1 (1), 15056
- https://doi.org/10.1038/nrdp.2015.56
Abstract
Alzheimer's disease is a chronic illness with long preclinical and prodromal phases (20 years) and an average clinical duration of 8–10 years. The disease has an estimated prevalence of 10–30% in the population >65 years of age with an incidence of 1–3%. Most patients with Alzheimer's disease (>95%) have the sporadic form, which is characterized by a late onset (80–90 years of age), and is the consequence of the failure to clear the amyloid-β (Aβ) peptide from the interstices of the brain. A large number of genetic risk factors for sporadic disease have been identified. A small proportion of patients (<1%) have inherited mutations in genes that affect processing of Aβ and develop the disease at a much younger age (mean age of ∼ 45 years). Detection of the accumulation of Aβ is now possible in preclinical and prodromal phases using cerebrospinal fluid biomarkers and PET. Several approved drugs ameliorate some of the symptoms of Alzheimer's disease, but no current interventions can modify the underlying disease mechanisms. Management is focused on the support of the social networks surrounding the patient and the treatment of any co-morbid illnesses, such as cerebrovascular disease.Keywords
This publication has 139 references indexed in Scilit:
- Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s DiseaseNeurotoxicity Research, 2013
- A European multicentre PET study of fibrillar amyloid in Alzheimer’s diseaseEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s diseaseActa Neuropathologica, 2010
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascadeThe Lancet Neurology, 2010
- Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer DiseaseArchives of Neurology, 2009
- Disclosure ofAPOEGenotype for Risk of Alzheimer's DiseaseThe New England Journal of Medicine, 2009
- A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous systemAnnals of Neurology, 2009
- Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivoNature Medicine, 2006
- Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving DonepezilJama-Journal Of The American Medical Association, 2004
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004